We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

M&A as Part of a Financing Round in the Life Sciences Sector

April 2008

VentureCapital Magazine No.4/2008, 34-35
Over the last few years there have been several transactions involving German biotech companies in which the creation of larger entities by way of merger or acquisition was combined with a financing round. Examples include the mergers of Graffinity Pharmaceuticals and MyoContract becoming Santhera Pharmaceuticals as well as Develogen and Peptor in 2004, of Curacyte and IBFB Pharma in 2005, of Combinature Biopharm, Athelas and Merlion Pharmaceuticals in 2006, and of Probiodrug and Ingenium in 2007. Such combination of M&A and financing rounds could gain importance as a transaction model on the way to further consolidation of the biotech industry in Germany.
Loading data